NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis $21.00 -0.05 (-0.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$20.75▼$21.2450-Day Range$14.70▼$21.7552-Week Range$13.27▼$22.00Volume31,658 shsAverage Volume90,644 shsMarket Capitalization$540.12 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Contineum Therapeutics alerts: Email Address Contineum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.3% Upside$28.00 Price TargetShort InterestBearish8.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.46Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.95) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector549th out of 936 stocksPharmaceutical Preparations Industry248th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingContineum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContineum Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Contineum Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.15% of the float of Contineum Therapeutics has been sold short.Short Interest Ratio / Days to CoverContineum Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldContineum Therapeutics does not currently pay a dividend.Dividend GrowthContineum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTNM. Previous Next 4.1 News and Social Media Coverage News SentimentContineum Therapeutics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Contineum Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for CTNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Contineum Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.Read more about Contineum Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Contineum Therapeutics are expected to grow in the coming year, from ($1.95) to ($1.83) per share.Read more about Contineum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Contineum Therapeutics Stock (NASDAQ:CTNM)Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More CTNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTNM Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comContineum Therapeutics (NASDAQ:CTNM) Shares Gap Up to $20.15June 13, 2024 | seekingalpha.comContineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track ModelJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 21, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)May 20, 2024 | businesswire.comContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsMay 16, 2024 | businesswire.comContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 11, 2024 | investing.comContineum Therapeutics Inc (CTNM)May 2, 2024 | finance.yahoo.comContineum Therapeutics Announces Pricing of Initial Public OfferingSee More Headlines Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/26/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CUSIPN/A CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside+33.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.20 Quick Ratio19.20 Sales & Book Value Annual Sales$50 million Price / Sales10.80 Cash Flow$1.24 per share Price / Cash Flow16.94 Book Value($3.72) per share Price / Book-5.65Miscellaneous Outstanding Shares25,720,000Free FloatN/AMarket Cap$540.12 million OptionableN/A BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Carmine N. Stengone MBA (Age 48)MS, President, CEO, Secretary & Director Comp: $790.3kMr. Peter T. Slover CPA (Age 49)Chief Financial Officer Comp: $569.7kDr. Daniel S. Lorrain Ph.D. (Age 55)Chief Science Officer Comp: $565.02kDr. Stephen L. Huhn F.A.A.P (Age 63)F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development Mr. Austin Chen Ph.D.SVP & Head of ResearchMr. Michael MayberrySenior Director & Corporate ControllerMore ExecutivesKey CompetitorsCatalyst PharmaceuticalsNASDAQ:CPRXArvinasNASDAQ:ARVNSyndax PharmaceuticalsNASDAQ:SNDXAmphastar PharmaceuticalsNASDAQ:AMPHZai LabNASDAQ:ZLABView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 20,232 shares on 7/26/2024Ownership: 0.079%View All Institutional Transactions CTNM Stock Analysis - Frequently Asked Questions How have CTNM shares performed this year? Contineum Therapeutics' stock was trading at $15.40 at the beginning of the year. Since then, CTNM shares have increased by 36.4% and is now trading at $21.00. View the best growth stocks for 2024 here. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) posted its quarterly earnings data on Thursday, May, 16th. The company reported ($3.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $3.02. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an initial public offering (IPO) on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00 per share. Who are Contineum Therapeutics' major shareholders? Contineum Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.08%). How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTNM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
